Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Is Up Big Today

By Brian Feroldi - May 14, 2019 at 3:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares rise after the company receives some praise from a pair of Wall Street analysts.

What happened

Shares of MannKind Corporation (NASDAQ: MNKD), a commercial-stage biopharma focused primarily on inhaled insulin, were up as much as 12% in afternoon trading on Tuesday. Shares had risen about 9% as of 3:45 p.m. EST.

So what

Investors can thank Robert Hazlett and Brian Marckx for today's jump.

Hazlett, an analyst at BTIG, initiated coverage on MannKind today and called shares a "buy." He also set a price target of $3, which is more than 150% higher than Monday's closing price. Hazlett told his investors that he believes that Afrezza will continue to grow and could eventually reach more than $350 million in peak sales in the U.S. That's a huge number when compared to MannKind's current market cap of about $250 million.

Marckx, an analyst at Zacks, was even more bullish on the company's near-term potential. He published a report stating that MannKind is worth $4 per share today.

Businesspeople cheering with their hands in the air.

Image source: Getty Images.

Traders bid up shares in response to the bullish sentiment.

Check out the latest MannKindearnings call transcript.

Now what

MannKind's most recent results were decent enough. Sales of Afrezza rose 49% to $5.1 million, and revenue from its collaborations totaled $12.4 million. That shrank the company's net loss to $14.9 million.

If MannKind can grow Afrezza so that its peak sales eventually reach $350 million and pull in additional money from partnership payments, its future is certainly looking bright. However, there's still a long road ahead of this company, and it will probably continue to post big losses in the meantime. That's a situation that I want no part of, so I'm content to keep my capital invested in more promising opportunities.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.